Immunosuppressive agents and interstitial lung disease: what are the risks?

Area of Science:

• Pulmonology
• Immunosuppressive Therapy
• Interstitial Lung Disease

Background:

• Idiopathic pulmonary fibrosis (IPF) is unlikely to respond to immunosuppressive therapies.
• Conversely, certain interstitial lung diseases (ILDs) show positive responses to immunosuppressive drug treatments.

Discussion:

• Immunosuppressive agents carry significant risks, including infection, diabetes, osteoporosis, myopathy, bone marrow suppression, hepatitis, urinary tract injury, and drug-induced pneumonitis.
• Clinicians must be vigilant regarding potential adverse reactions and implement pre-therapy screening (e.g., tuberculosis, hepatitis, renal insufficiency) and ongoing monitoring.

Key Insights:

• Some ILDs, such as cellular non-specific interstitial pneumonia, organizing pneumonia, and sarcoidosis, respond well to immunosuppressive therapies, including corticosteroids.
• Steroid-sparing agents can mitigate corticosteroid side effects and potentially improve treatment efficacy for conditions like sarcoidosis or connective tissue disease-associated ILDs.

Outlook:

• Careful patient selection and risk management are crucial when considering immunosuppressive therapy for ILDs.
• Further research into targeted therapies for IPF and optimizing immunosuppressive strategies for responsive ILDs is warranted.